|
|
|
|
|
|
|
|
|
|
 |
|
|
Biodesix  Member Login |
|
|
Non-Executive Board Members
Robert E. Cawthorn
Chairman of the Board of Directors
|
| |
Mr. Cawthorn, Chairman of the Board of Biodesix and a major investor in the Company.
Mr. Cawthorn retired in 2001 as a Managing Director of Global Health Care Partners
of DLJ Merchant Banking Partners. He retired as Chief Executive Officer of
Rhône-Poulenc Rorer Inc. in May 1995 and as Chairman in May 1996, after nearly
four decades in the pharmaceutical, biotechnology and animal health industries.
Mr. Cawthorn was an executive with Pfizer International for 17 years and was the
first president of Biogen Inc. (now Biogen/Idec Inc.) before joining Rorer Group
in 1982. He is credited with transforming Rorer into a major research-driven
pharmaceutical company, largely through acquisitions and mergers, culminating
in the successful merger that created Rhône-Poulenc Rorer in 1990. Mr. Cawthorn
is Chairman of Actelion Ltd. and also serves as a director of The March Group,
NextPharm Technologies, and Leerink Swann & Co. Mr. Cawthorn is a graduate of
Cambridge University, England.
|
Jack W. Schuler
Director
|
| |
Jack W. Schuler joined Biodesix’s Board of Directors in June 2008.
He also serves as on the Board of Directors of Stericycle, Inc. From January 1987 to August 1989, he served
as President and Chief Operating Officer of Abbott Laboratories,
a diversified health care company which he joined in 1972 and where
he held a number of management and marketing positions and served as
a director from April 1985 to August 1989. He served as chairman of
the board of directors of Ventana Medical Systems, Inc. prior to its
acquisition by Roche in February 2008, and as a director of Medtronic, Inc.
and Quidel Corporation, a leader in point-of-care rapid diagnostic tests.
He is the co-founder of Crabtree Partners, a private investment partnership
in Lake Forest, Illinois, which was formed in June 1995. Mr. Schuler received
a B.S. degree in Mechanical Engineering from Tufts University and an M.B.A. degree
from the Stanford University Graduate School of Business Administration.
|
John Patience
Director
|
| |
John Patience joined Biodesix’s Board of Directors in June 2008. Mr. Patience
also serves as a director of Stericycle, Inc. and has done so since its incorporation in March 1989.
He is a co-founder and partner of Crabtree Partners, a private investment partnership in Lake Forest,
Illinois, which was formed in June 1995. From January 1988 to March 1995, Mr. Patience was a general
partner of Marquette Venture Partners, L.P., a venture capital fund which he co-founded. Mr. Patience
was Vice Chairman of Ventana Medical Systems, Inc. prior to its acquisition by Roche in February 2008.
Mr. Patience received B.A. and Bachelor of Law degrees from the University of Sydney in Sydney, Australia,
and an M.B.A. degree from the Wharton School of Business of the University of Pennsylvania.
|
Executive Board Members
David Brunel
Executive Chairman
|
| |
Mr. Brunel has been involved in enterprise software for over 25 years and has been involved
in molecular diagnostics since 2000. Mr. Brunel was a founder and was CEO of Unidata, Inc.
when it merged with Vmark Software to create Ardent Software, Inc., where he was President
and COO. He was also a member of the Board of Ardent until it was sold to Informix
in 1999. Mr. Brunel was also a co-founder and President of SomaLogic, Inc. a
company focused on creating protein capture arrays for sensitive, high-throughput,
quantitative diagnostics. Mr. Brunel is also on the board of Anark Corporation and
Xyleme, Inc.
|
Heinrich Röder, D.Phil.
Chief Technology Officer and Board Member
|
| |
Dr. Röder is author or co-author of more than 100 publications/talks in theoretical
physics and computational sciences. Dr. Röder obtained his D.Phil at Oxford
University, and went on to become an eminent theoretical physicist with positions
at University of Hanover and Bayreuth (Germany) and Los Alamos National Laboratory.
He has led projects involving the diagonalization of gigadimensional matrices, has
done pioneering work in the microscopic mechanisms of colossal magneto resistive
perovskites, and initiated the first use of large-scale inverse problem techniques
in the analysis of neutron scattering data. Recruited from Los Alamos, Dr. Röder
serves as Biodesix’s CTO, leading the Research and Development side of the Company
and designing functionality for next generation products and services. Dr. Röder
is a Rhodes Scholar.
|
|
|
|
|
 Copyright © 2007 Biodesix Inc. |